• ADHD

Strattera Generic Name & Formulations

General Description

Atomoxetine HCl 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg; caps.

Pharmacological Class

Selective norepinephrine reuptake inhibitor.

How Supplied



Generic Availability


Strattera Indications


Attention deficit hyperactivity disorder (ADHD).

Strattera Dosage and Administration

Adults and Children

Swallow whole. Give once daily in the AM, or in 2 evenly divided doses (in AM and late afternoon/early PM). <6yrs: not established. Acute: ≥6yrs (≤70kg): initially 0.5mg/kg/day; increase after at least 3 days to 1.2mg/kg/day; max 1.4mg/kg or 100mg/day (whichever is less); (>70kg): initially 40mg/day; increase after at least 3 days to 80mg/day, then after 2–4 weeks may increase to max 100mg/day. Maintenance: 6–15yrs: continue with same dose, reevaluate periodically; see full labeling. Concomitant potent CYP2D6 inhibitors: titrate above initial dose at 4-week intervals only if needed. Hepatic impairment (moderate): reduce dose by 50%; (severe): reduce dose by 75%. May discontinue without tapering.

Strattera Contraindications


During or within 14 days of MAOIs. Narrow angle glaucoma. Pheochromocytoma or history of. Severe cardiovascular disorders that might deteriorate with clinically important increases in HR and BP.

Strattera Boxed Warnings

Boxed Warning

Suicidal ideation in children and adolescents.

Strattera Warnings/Precautions


Increased risk of suicidal ideation in children and adolescents. Monitor closely for clinical worsening, suicidality and unusual changes in behavior (esp. during initial therapy and dose adjustments). Severe liver injury (discontinue if jaundice or elevated liver enzymes occur; do not restart). Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Assess cardiovascular status and do physical exam. Hypertension. Tachycardia. Cardio- or cerebrovascular disease. Psychoses. Screen for bipolar disorder prior to initiation. Depression. Monitor growth, BP/pulse (esp. at baseline and after dose increases), emergence or worsening of aggressive behavior/hostility. Poor metabolizers (CYP2D6). Reevaluate periodically. Elderly. Labor & delivery. Pregnancy. Nursing mothers.

Strattera Pharmacokinetics

See Literature

Strattera Interactions


MAOIs: see Contraindications. May be potentiated by potent CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Increased cardiovascular effects with albuterol, pressor agents (eg, dobutamine, dopamine).

Strattera Adverse Reactions

Adverse Reactions

Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence, weight loss, dizziness, headache, mood swings, tachycardia, hypertension, orthostatic hypotension, mydriasis; rare: severe liver injury, priapism, anaphylaxis. Adults also: constipation, dry mouth, insomnia, sexual dysfunction, urinary retention/hesitation, dysuria, dysmenorrhea, hot flush.

Strattera Clinical Trials

See Literature

Strattera Note

Not Applicable

Strattera Patient Counseling

See Literature